Blue Earth Diagnostics Announces Results on Clinical Factors Impacting Detection Rates from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

Oral presentation highlighted at American Society for Radiation Oncology (ASTRO) 2022 Annual Meeting

Related Keywords

Germany ,United States ,San Antonio ,Texas ,Munich ,Bayern ,Scintomics Gmb ,Davide Gauden ,Benjamin Lowentritt ,Technical University Of Munich ,American Society For Radiation Oncology ,Drug Administration ,Study Group ,Chesapeake Urology Research Associates ,Blue Earth Diagnostics ,Prostate Specific Antigen ,Prostate Specific Membrane Antigen Targeted ,American Society ,Radiation Oncology ,New Drug Application ,Chief Executive Officer ,Blue Earth ,Radiohybrid Prostate Specific Membrane Antigen ,Technical University ,Scintomics Gmbh ,